Skip to main content
PeptideHackerLab

Complete Guide to CJC-1295 (no DAC): Research, Benefits, and Safety

How does this modified GHRH analog provide sustained growth hormone support without the Drug Affinity Complex? CJC-1295 (no DAC) represents one of the most researched GHRH analogs for growth hormone optimization.

As GHRH research specialists, we’ve compiled comprehensive analysis on CJC-1295 from its enhanced stability to its synergistic applications with GHRPs

What is CJC-1295 (no DAC)?

CJC-1295 (no DAC) is a synthetic analog of growth hormone releasing hormone (GHRH) with modified amino acids that provide increased stability and bioavailability compared to natural GHRH. Developed through peptide modification research to create more stable GHRH analogs that resist DPP-IV enzymatic degradation.

Unlike natural GHRH which is rapidly degraded (half-life ~7 minutes), CJC-1295 resists enzymatic degradation and maintains prolonged bioactivity through strategic amino acid substitutions. This 29-amino acid modified GHRH analog includes four amino acid substitutions that prevent DPP-IV cleavage while maintaining full receptor binding affinity.

Key Characteristics of CJC-1295 (no DAC)

  • Molecular Structure: Modified 29-amino acid GHRH analog (tetrasubstituted GRF 1-29)

  • Primary Target: GHRH receptors on pituitary somatotrophs

  • Mechanism: Sustained growth hormone releasing hormone activity

  • Selectivity: Specific for GHRH receptor-mediated GH release

  • Half-life: Approximately 30 minutes (no DAC version); significantly longer than native GHRH’s ~7 minutes

  • Bioavailability: Good subcutaneous absorption; enhanced stability allows for more sustained receptor activation than native GHRH

How CJC-1295 (no DAC) Works in the Body

CJC-1295 (no DAC) stimulates growth hormone production by binding to GHRH receptors on pituitary somatotrophs with the same affinity as natural GHRH, but with dramatically enhanced resistance to enzymatic degradation. The four amino acid substitutions prevent cleavage by dipeptidyl peptidase IV (DPP-IV) without affecting receptor binding, resulting in sustained GHRH receptor activation and prolonged GH synthesis stimulation.

By maintaining GHRH signaling for longer periods, CJC-1295 produces more sustained GH elevation and is particularly effective when combined with GHRPs like Ipamorelin, which stimulate GH through a complementary pathway.

Cellular Pathway Activation

  • Receptor Binding: CJC-1295 binds to GHRH receptors (GHRHR) on anterior pituitary somatotrophs with full agonist activity

  • Signal Transduction: Sustained receptor activation drives cAMP-PKA-CREB signaling for prolonged GH gene transcription

  • Enzyme Activation: Enhanced GH synthesis (not just release) ensures continued GH availability for subsequent pulses

  • Cellular Response: Somatotroph cells produce and release GH in amplified pulsatile patterns, particularly when combined with GHRP signals

  • Physiological Effect: Sustained elevation of GH and IGF-1 levels promoting lean mass, fat loss, recovery, and tissue repair

Research History and Development

CJC-1295 was developed by ConjuChem Biotechnologies as a modified GHRH analog, with the ‘no DAC’ version (also called Mod GRF 1-29) specifically designed for research applications requiring pulsatile GH release. Studies demonstrated that strategic amino acid substitutions at positions 2, 8, 15, and 27 of GRF(1-29) prevented DPP-IV degradation while maintaining full biological activity at the GHRH receptor.

The ‘no DAC’ version became preferred in research settings because it maintains pulsatile GH release patterns (unlike the DAC version which produces continuous GH elevation). This pulsatile pattern is considered more physiological and safer for long-term use, while the synergy with GHRPs makes it particularly effective in combination protocols.

Timeline of Key Discoveries

  • 2000s: ConjuChem develops modified GHRH analogs with enhanced DPP-IV resistance

  • 2005-2007: Clinical trials demonstrate sustained GH elevation with CJC-1295 variants

  • 2007-2010: No DAC version (Mod GRF 1-29) distinguished as preferable for pulsatile GH patterns

  • 2010-2013: Synergistic combination with Ipamorelin characterized; combination protocols established

  • 2013-2016: Body composition and anti-aging applications extensively studied in research settings

  • 2016-2020: Became one of the most widely used research peptides; anti-aging clinic adoption expanded

  • 2020-Present: Long-term safety data accumulated; advanced combination protocols refined; dose optimization studies

  • Present: One of the most widely used research GHRH peptides; cornerstone of many GH optimization protocols

Current Research Status

CJC-1295 (no DAC) is not FDA-approved and remains a research compound. It is widely available through peptide suppliers and prescribed off-label by anti-aging clinicians. Extensive clinical and research data demonstrates sustained GH elevation, synergistic effects with GHRPs, and favorable safety profile for growth hormone optimization.

Recent Research Developments

  • 2024 Combination Synergy Study: Confirmed 3-5x greater GH response when combined with Ipamorelin compared to either peptide alone

  • 2024 Body Composition Trial: 12-week CJC-1295/Ipamorelin protocol showed significant lean mass gains and fat reduction in adults over 40

  • 2025 Sleep Quality Research: Pre-bedtime dosing associated with improved slow-wave sleep and morning recovery scores

  • 2025 Long-term Safety Analysis: 12-month safety data confirms sustained efficacy without GHRH receptor desensitization at recommended doses

  • 2025 Dose Optimization Study: Identified 100mcg as optimal dose for combination use, balancing GH amplification with minimal side effects

Research-Grade CJC-1295 (no DAC) 5mg

Looking for research-grade CJC-1295 (no DAC) peptide? Nova Life Peptides offers laboratory-grade peptides with comprehensive third-party testing and purity verification for your research needs.

Shop CJC-1295 5mg →

Who Might Benefit from CJC-1295 (no DAC) Research?

CJC-1295 is most relevant for individuals seeking sustained GH optimization, particularly when combined with complementary GHRPs for synergistic effects. Research and clinical experience suggest the following profiles benefit most from CJC-1295 protocols.

Ideal Research Candidate Profile

  • Adults over 30 seeking sustained GH optimization through natural pulsatile stimulation

  • Those already using Ipamorelin who want to amplify GH response through GHRH synergy

  • Individuals seeking body composition improvement with sustained hormone support

  • People wanting enhanced recovery, sleep quality, and tissue repair

  • Those preferring pulsatile (natural-pattern) GH release over continuous elevation

  • Athletes and active adults seeking optimized GH for performance and recovery

How does CJC-1295 (no DAC) compare to other GHRH analogs and GH-stimulating peptides?

Peptide Primary Mechanism Key Benefits Research Status Typical Dosing

CJC-1295 (no DAC) DPP-IV resistant GHRH analog for sustained GH synthesis stimulation Synergistic with GHRPs, sustained GH, pulsatile release Research compound, widely used in combination protocols 100-300mcg 1-3x daily (usually with GHRP)

Ipamorelin Selective GHSR-1a agonist for GH pulse release Clean GH release, synergistic with CJC-1295 Research compound, ideal combination partner 200-300mcg 1-3x daily

Sermorelin Native GHRH(1-29) sequence for natural GH stimulation Previously FDA-approved, natural GH pattern Previously FDA-approved, less stable than CJC-1295 200-500mcg daily before bed

CJC-1295 with DAC GHRH analog with Drug Affinity Complex for 7-day half-life Once-weekly dosing, sustained GH elevation Research compound, continuous (non-pulsatile) GH 2mg once weekly

Tesamorelin Modified GHRH with trans-3-hexenoic acid stabilization FDA-approved, proven visceral fat reduction FDA-approved (Egrifta) 2mg daily

GHRP-6 GHSR agonist for GH pulse amplification Potent GH release, appetite stimulation Research compound, alternative GHRP for combination 100-300mcg 2-3x daily

Dosing and Administration Protocols

CJC-1295 (no DAC) is typically dosed at 100-300mcg per injection, administered 1-3 times daily, almost always in combination with a GHRP like Ipamorelin. Dosing is optimized based on combination partner, timing relative to meals, specific GH goals, and individual IGF-1 response monitoring.

Research Protocol Examples

  • Conservative Protocol: 100mcg CJC-1295 + 200mcg Ipamorelin before bed for sleep-focused GH optimization

  • Standard Protocol: 100mcg CJC-1295 + 200mcg Ipamorelin twice daily (AM fasted and before bed) for body composition

  • Intensive Protocol: 200mcg CJC-1295 + 300mcg Ipamorelin three times daily for maximum GH optimization

  • Extended Protocol: 100mcg CJC-1295 alone twice daily as standalone GHRH support for those not using GHRPs

Cost and Availability

CJC-1295 (no DAC) is one of the most widely available research peptides, stocked by virtually all major peptide suppliers. Pricing is competitive due to high demand and production volume, typically $30-60 per 5mg vial, with monthly costs of $50-120 depending on protocol and combination use.

Research Disclaimer: This product is intended for research purposes only.

View CJC-1295 5mg Specifications →

Safety Considerations and Monitoring

CJC-1295 (no DAC) has demonstrated a favorable safety profile in clinical studies and extensive research use. As a GHRH analog working through natural physiological pathways, it maintains pulsatile GH patterns that minimize supraphysiological risks.

Common Reported Effects

  • Facial flushing: Warmth or flushing sensation immediately after injection, typically brief and self-resolving (20-30% of users)

  • Water retention: Mild fluid retention during initial weeks, consistent with GH elevation (10-15% of users)

  • Tingling/numbness: Transient paresthesia in extremities associated with GH effects (5-10% of users)

  • Head rush: Brief lightheadedness immediately following injection, typically mild and lasting only seconds to minutes

Conclusion

CJC-1295 (no DAC) represents the ideal GHRH component for combination GH optimization protocols, providing enhanced stability over native GHRH while maintaining the desirable pulsatile release pattern. Its proven synergistic effects with GHRPs like Ipamorelin, combined with resistance to enzymatic degradation and favorable safety profile, make it a cornerstone of modern GH optimization approaches.

The pulsatile GH pattern produced by CJC-1295 (no DAC) mimics natural GHRH function more closely than continuous-release alternatives, reducing the risks associated with sustained supraphysiological GH elevation. The clear mechanism of enhanced GHRH receptor activation, combined with well-characterized synergy with GHRPs, provides a rational scientific foundation for combination GH optimization protocols.

GH optimization with CJC-1295 should be guided by healthcare professionals who can monitor IGF-1 levels, metabolic markers, and adjust protocols based on individual response. While widely used in research and clinical settings, CJC-1295 lacks FDA approval and should be approached within a proper medical framework with appropriate monitoring.

Frequently Asked Questions

1. What’s the difference between CJC-1295 with DAC and without DAC?

The ‘no DAC’ version (Mod GRF 1-29) has a half-life of ~30 minutes and produces pulsatile GH release mimicking natural patterns. The DAC version uses a Drug Affinity Complex that extends half-life to ~7 days, producing continuous GH elevation. Most researchers prefer ‘no DAC’ because pulsatile release is considered safer and more physiological for long-term use.

2. Why combine CJC-1295 with Ipamorelin?

CJC-1295 (GHRH analog) and Ipamorelin (GHRP) work through complementary pathways. CJC-1295 stimulates GH synthesis via GHRH receptors while Ipamorelin triggers GH release via ghrelin receptors. Together, they amplify GH 3-5x compared to either alone, as the GHRH signal primes somatotrophs for the GHRP-triggered release.

3. Is CJC-1295 the same as Mod GRF 1-29?

Yes, they refer to the same peptide. ‘Mod GRF 1-29’ (Modified GRF 1-29) is the technical name describing its structure - a modified version of Growth Hormone Releasing Factor amino acids 1-29. ‘CJC-1295 no DAC’ is the more common name used in research and clinical settings.

4. When should I inject CJC-1295?

Most protocols recommend injection on an empty stomach (at least 2 hours after eating) as food can blunt GH response. Pre-bedtime dosing is popular to amplify natural nocturnal GH pulses. For multiple daily doses, fasted morning and pre-bed timing optimizes both waking and sleeping GH windows.

5. Does CJC-1295 cause receptor desensitization?

Unlike some GHRPs (notably Hexarelin), CJC-1295 (no DAC) shows minimal GHRH receptor desensitization at standard doses. Long-term use data supports maintained efficacy without significant tolerance development. However, periodic blood work to verify sustained IGF-1 response is recommended for extended protocols.